21 SHARE-BASED PAYMENTS (CONTINUED) During the 2023 financial year, the Company issued 650,000 options under INOVIQ’s Incentive Option Plan. 500,000 of these were issued to the CEO, Dr Leearne Hinch, under the Company’s Incentive Option Plan, in consideration for services provided by Dr Hinch in her role as CEO. The remaining 150,000 options were issued to the CFO/Company Secretary Mr Mark Edwards in consideration for services provided. 22 AUDITOR’S REMUNERATION For the year ended 30 June 2023 $ For the year ended 30 June 2022 $ Amounts received or due and receivable by the Company’s auditors Grant Thornton for: - Auditing the statutory financial report of the Parent company of the Group and auditing the statutory financial reports of any controlled entity. 122,460 107,431 122,460 107,431 23 RELATED PARTY DISCLOSURES Other related party transactions (a) Wholly Owned Group Transactions Details of interests in controlled entities are set out in Note 24. (b) Ultimate Parent Company INOVIQ Limited is the ultimate legal Australian holding Company. (c) Transactions with Other Related Parties The Company does not have any transactions with other related parties. 24 CONTROLLED ENTITIES Consolidated entities of INOVIQ Ltd Country of Incorporation Equity Interest held % 30 June 2023 30 June 2022 Sienna Cancer Diagnostics Limited Australia 100 100 INOVIQ Inc. (formerly Sienna Cancer Diagnostics Inc.) U.S.A. 100 100 BARD1AG SA Switzerland - 100 BARD1AG SA was disposed of during the current period. Refer Note 29 for additional information. 25 EVENTS SUBSEQUENT TO BALANCE DATE The following announcements were made via the ASX announcement platform since the end of the reporting period: – On 6 July 2023, the Company announced that it and Promega signed a global joint marketing agreement for INOVIQ’s EXO-NET exosome capture technology and Promega Nucleic Acid purification systems; and – On 9 August 2023, the Company announced results of its Ovarian Cancer Serum equivalence study, showing EXO‑NET successfully isolated extracellular vesicles (EVs) from both plasma and serum samples, with variability in results noted for long-term biobanked plasma and serum samples. At the date of this report, other than that outlined above, there have been no matters or circumstances that have arisen since the end of the period which significantly, or may significantly effect: – The Group’s operations in future years; – The results of those operations in future years; or – The Group’s state of affairs in future years. 63 Annual Report 2023
RkJQdWJsaXNoZXIy MjE2NDg3